What is Geneuro Sa's official website?

Geneuro Sa's website is geneuro.com

What is Geneuro Sa's industry?

Geneuro Sa's industry is Biotechnology Research

Who are Geneuro Sa's top competitors?

Geneuro Sa's top competitors are , , , , , ,

When was Geneuro Sa founded?

Geneuro Sa's founding year is 2006

Geneuro Sa company information, Employees & Contact Information

Updated May 2026

Quick answer

Geneuro Sa is a Biotechnology Research company and founded in 2006. It has approximately 16 employees on record. Contact data was last refreshed in May 2026. Find Geneuro Sa's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Geneuro Sa email format Geneuro Sa management contacts

Related company profiles:

GeNeuro is a biotechnology company developing innovative treatments against inflammatory and neurodegenerative disorders associated with Human Endogenous Retroviruses (HERVs). We are committed to fight the progression of disability in Multiple Sclerosis #FightMS and other neurodegenerative diseases #ALS #LongCOVID Our Community Guidelines: http://bit.ly/36y9YCE

Employees: 16
Founded: 2006
Phone: 41227945085
Email: co****@****uro.com
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: geneuro.com
Keywords: Multiple Sclerosis, Progressive MS, ALS, SLA, HERV, Autoimmune diseases.
Competitors: Selexis SA, Light Chain Bioscience | Novimmune SA, GliaPharm SA, Addex Therapeutics, Neurix SA, Amal Therapeutics, ADC Therapeutics, Soligenix, Inc., uniQure, AC Immune.

Geneuro Sa Questions

News

GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report - Business Wire

GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report Business Wire

GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting - Yahoo Finance

GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting Yahoo Finance

GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS - Business Wire

GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS Business Wire

GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results - Yahoo Finance

GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results Yahoo Finance

Geneuro SA Postpones Publication Of Half-Yearly Financial Report - TradingView

Geneuro SA Postpones Publication Of Half-Yearly Financial Report TradingView

Geneuro SA postpones publication of half-yearly financial report - MarketScreener

Geneuro SA postpones publication of half-yearly financial report MarketScreener

GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium - Business Wire

GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium Business Wire

GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025 - Yahoo Finance

GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025 Yahoo Finance

Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium - TradingView

Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium TradingView

Geneuro SA announces extension of its definitive Debt Restructuring moratorium - MarketScreener

Geneuro SA announces extension of its definitive Debt Restructuring moratorium MarketScreener

GeNeuro's long COVID trial fails, triggering layoffs and search for strategic alternatives - Fierce Biotech

GeNeuro's long COVID trial fails, triggering layoffs and search for strategic alternatives Fierce Biotech

Temelimab Proves Safe at Highest Dose for Multiple Sclerosis in Phase 2 Topline Data - NeurologyLive

Temelimab Proves Safe at Highest Dose for Multiple Sclerosis in Phase 2 Topline Data NeurologyLive

HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms - Frontiers

HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms Frontiers

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients - medRxiv

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients medRxiv

Will GeNeuro SA (GEM) stock benefit from mergers - 2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - newser.com

Will GeNeuro SA (GEM) stock benefit from mergers - 2025 Price Action Summary & Free Real-Time Volume Trigger Notifications newser.com

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments - Greater Geneva Bern area

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments Greater Geneva Bern area

Antibodies Against Viral Protein Tied to Better Survival Rate in ALS - ALS News Today

Antibodies Against Viral Protein Tied to Better Survival Rate in ALS ALS News Today

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients - medRxiv

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients medRxiv

GeNeuro's experimental multiple sclerosis drug shows hints it may help treat COVID-19 - Fierce Biotech

GeNeuro's experimental multiple sclerosis drug shows hints it may help treat COVID-19 Fierce Biotech

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis - Labiotech.eu

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis Labiotech.eu

Servier drops GeNeuro’s multiple sclerosis drug after midphase miss - Fierce Biotech

Servier drops GeNeuro’s multiple sclerosis drug after midphase miss Fierce Biotech

Companies like Geneuro Sa

Top Geneuro Sa Employees

Jesús Martin Garcia

Entrepreneur & Executive Leader | Strategy, Innovation & Value Creation In Health & Technology

Plan-Les-Ouates, Geneva, Switzerland, Switzerland

View

2
eclosion.com, geneuro.com

1 +417920XXXXX
Julie MEDINA

n/a

Greater Lyon Area, France

View

2
sanofipasteur.com, geneuro.com

1 +33 4 3XXXXXXXXXX
David Leppert

Senior Research Associate At Department Of Neurology, University Hospital Basel

Basel, Basel, Switzerland, Switzerland

View

2
unibas.ch, novartis.com
Giacomo Di Nepi

Advisor And Non Executive Director

N/a

View

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Geneuro Sa company information, Employees & Contact Information

Quick answer

Explore related pages

Company Details

Geneuro Sa Questions

What is Geneuro Sa's helpline number?

What is Geneuro Sa's official website?

What is Geneuro Sa's LinkedIn profile?

How many employees are working in Geneuro Sa right now?

What is Geneuro Sa's industry?

What are Geneuro Sa's top competitors?

What is Geneuro Sa's support email address?

What are Geneuro Sa's categories?

When was Geneuro Sa founded?

News

GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report - Business Wire

GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting - Yahoo Finance

GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS - Business Wire

GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results - Yahoo Finance

Geneuro SA Postpones Publication Of Half-Yearly Financial Report - TradingView

Geneuro SA postpones publication of half-yearly financial report - MarketScreener

GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium - Business Wire

GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025 - Yahoo Finance

Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium - TradingView

Geneuro SA announces extension of its definitive Debt Restructuring moratorium - MarketScreener

GeNeuro's long COVID trial fails, triggering layoffs and search for strategic alternatives - Fierce Biotech

Temelimab Proves Safe at Highest Dose for Multiple Sclerosis in Phase 2 Topline Data - NeurologyLive

HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms - Frontiers

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients - medRxiv

Will GeNeuro SA (GEM) stock benefit from mergers - 2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - newser.com

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments - Greater Geneva Bern area

Antibodies Against Viral Protein Tied to Better Survival Rate in ALS - ALS News Today

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients - medRxiv

GeNeuro's experimental multiple sclerosis drug shows hints it may help treat COVID-19 - Fierce Biotech

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis - Labiotech.eu

Servier drops GeNeuro’s multiple sclerosis drug after midphase miss - Fierce Biotech

Companies like Geneuro Sa

Uniqure

Ac Immune

Adc Therapeutics

Addex Therapeutics

Neurix Sa

Gliapharm Sa

Light Chain Bioscien...

Selexis Sa

Amal Therapeutics

Soligenix, Inc.

Top Geneuro Sa Employees

Jesús Martin Garcia

Entrepreneur & Executive Leader | Strategy, Innovation & Value Creation In Health & Technology

Julie MEDINA

n/a

David Leppert

Senior Research Associate At Department Of Neurology, University Hospital Basel

Giacomo Di Nepi

Advisor And Non Executive Director

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data